

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gladyshev et al.

Art Unit: 1642

Application No. 09/676,718

CERTIFICATE OF MAILING

Filed: September 28, 2000

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on January 7, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

For: MAMMALIAN SELENOPROTEIN  
DIFFERENTIALLY EXPRESSED IN TUMOR  
CELLS

Examiner: Stephen L. Rawlings, Ph.D.

Date: January 7, 2003

*[Signature]*  
Agent for Applicants

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

**RECEIVED**

JAN 17 2003

TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT**

This is a response to the Restriction requirement dated December 3, 2002. A one-month period for response was set, making a reply due by January 3, 2003. A request for a one-month extension of time and the appropriate fee are enclosed, now making the reply due by February 3, 2003.

Applicants provisionally elect group I (claims 51-53, 55, 60, 63, 64, 66-77 and 80-82), with traverse.

**Remarks**

The Examiner has restricted pending claims 51-53, 55, 60, 63-64 and 66-82 into eight groups. However, the restriction requirement incorrectly restricted subsequences into separate claim groups, and restricted dependent claims from independent claims. Reconsideration of the restriction requirement is therefore requested.

As discussed on page 4 of the previous Amendment and Response to Restriction Requirement filed by the Applicants on September 3, 2002, SEQ ID NO: 4 is a subsequence of SEQ ID NO: 1 (amino acids 27-162 of SEQ ID NO: 1 are shown as SEQ ID NO: 4). Therefore,